Meeting
2022 ASCO Annual Meeting
Decreasing HPK1 expression in CD19 CAR-T cells: A novel strategy to overcome challenges of cell therapy for adult (r/r) B-ALL.
Authors
Na Zhang
Department of Hematology, Xijing Hospital, Xi'an, China
Na Zhang , Jingwen SI , Guang LI , Yu WANG , Fei LONG , Tantan WANG , Yanping Song , Xuebin Liao , Guangxun Gao , Dimiter Stanchev Dimitrov
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04037566
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7041)
DOI
10.1200/JCO.2022.40.16_suppl.7041
Abstract #
7041
Poster Bd #
272
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Effect of bispecific B7H3 x CD19 CAR T cells on host CD19 expression and CAR T cell engraftment.
First Author: Navin R. Pinto
Poster
2023 ASCO Annual Meeting
Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.
First Author: Shiqi Li
Poster
2022 ASCO Annual Meeting
STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.
First Author: Navin R. Pinto
Poster
2018 ASCO Annual Meeting
Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions.
First Author: Jennifer N. Brudno